Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018

Pharmaceutical Investing

Actinium Pharmaceuticals (NYSE:ATNM) announced that it has issued a letter to investors providing a company update and outlook for 2018. As quoted in the press release: Sandesh Seth, Actinium’s Chairman and CEO said, “In December 2017, we announced several exciting developments that exemplify Actinium’s functionality, enhanced capabilities, and most importantly, a focus on execution. We finished 2017 …

Actinium Pharmaceuticals (NYSE:ATNM) announced that it has issued a letter to investors providing a company update and outlook for 2018.
As quoted in the press release:

Sandesh Seth, Actinium’s Chairman and CEO said, “In December 2017, we announced several exciting developments that exemplify Actinium’s functionality, enhanced capabilities, and most importantly, a focus on execution. We finished 2017 with strong momentum in our Iomab-B and Actimab-A clinical programs, added to our CD33 program and growing bone marrow transplant franchise with the announcement of Actimab-MDS and reinvigorated our research and development efforts with the launch of our AWE Program. This momentum gives our team phenomenal energy for 2018 and we look forward to continued strong execution on the numerous clinical milestones that we expect can unlock significant value for investors.”

Click here to read the full press release.

clinical milestones company update transplant Company News